公开(公告)号：US20070166372A1

公开(公告)日：2007-07-19

申请号：US11641093

申请日：2006-12-19

申请人： Huimin He Huang ,  Caigu Huang

发明人： Huimin He Huang ,  Caigu Huang

IPC分类号： A61K31/4184 ,  A61K9/48 ,  A61K9/20 ,  A61K9/14

CPC分类号： A61K9/2018 ,  A61K9/146 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/4184

摘要： A novel coprecipitate of amorphous valsartan with a pharmaceutically acceptable carrier, e.g. polyvinylpyrolidone (PVP), crosslinked-polyvinylpyrolidone, polyvinylpyrolidone vinyl acetate copolymer (PVP-VA64), a process for the preparation of said novel co-precipitate and the use of said novel coprecipitate in the treatment and/or prophylaxis of hypertension, cardiovascular diseases and conditions associated with thereof and certain complications thereof, are disclosed. A novel solid solution of amorphous valsartan with a pharmaceutically acceptable carrier, preferably with polyethyelene glycol PEG from 4000 to 20,000 of average mol. wt., a process for the preparation thereof and use are disclosed. The said novel coprecipitate of amorphous valsartan and the said novel solid solution of valsartan are stable and may be particularly suitable for pharmaceutical dosage forms.

摘要翻译： 具有药学上可接受的载体的无定形缬沙坦的新型共沉淀物，例如 聚乙烯吡咯烷酮（PVP），交联聚乙烯吡咯烷酮，聚乙烯吡咯烷酮乙酸乙烯酯共聚物（PVP-VA64），制备所述新型共沉淀物的方法和所述新型共沉淀物在治疗和/或预防高血压，心血管疾病和 公开了与其相关的病症及其某些并发症。 具有药学上可接受的载体的无定形缬沙坦的新型固溶体，优选具有平均mol的4000至20,000的聚乙二醇PEG。 公开了其制备方法和用途。 所述无定形缬沙坦的新型共沉淀物和所述新型缬沙坦固溶体是稳定的，并且可能特别适用于药物剂型。